VERTEX PHARMACEUTICALS INC / MA (VRTX) Financial Forecast
United States · Health Care · USD (Millions) · Annual
Key financials
USD|Millions
ROE
22.54%
2025 (actual)
ROA
16.41%
2025 (actual)
Gross Margin
86.24%
2025 (actual)
Net Margin
32.94%
2025 (actual)
Total Assets
$25,643.00M
2025 (actual)
Net Income
$3,953.20M
2025 (actual)
Valuation
$114,909.04M
2026 (forecast)
Stock Price
$453.36
Historical & projected performance
USD|Millions
Reported figures and Equlion model projections for the next 5 years.
ROE
-7 pt
Company
Sector average
ROA
-3 pt
Company
Gross Margin
-6.2 pt
Company
Sector average
Net Margin
-2.4 pt
Company
Total Assets
+136.3%
Company
Sector average (own scale)
Net Income
+92.7%
Company
Valuation
+37.5%
Company
Sector average
Stock Price
+37.5%
Company
Sector average (own scale)
Amounts in USD (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.
Want the full financial forecast report for VERTEX PHARMACEUTICALS INC / MA? It covers the balance sheet, income statement, cash flow and Equlion model projections.